Mesa Laboratories, Inc. (MLAB) Director Seg Ventures, Llc Buys 30,000 Shares of Stock

Share on StockTwits

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Seg Ventures, Llc acquired 30,000 shares of Mesa Laboratories stock in a transaction on Friday, October 12th. The shares were bought at an average cost of $21.52 per share, with a total value of $645,600.00. Following the completion of the transaction, the director now owns 120,000 shares of the company’s stock, valued at $2,582,400. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Seg Ventures, Llc also recently made the following trade(s):

  • On Friday, December 21st, Seg Ventures, Llc bought 40,000 shares of Mesa Laboratories stock. The stock was acquired at an average cost of $24.75 per share, with a total value of $990,000.00.
  • On Sunday, December 30th, Seg Ventures, Llc bought 20,000 shares of Mesa Laboratories stock. The stock was acquired at an average cost of $23.10 per share, with a total value of $462,000.00.

Shares of Mesa Laboratories stock opened at $181.50 on Friday. The stock has a market capitalization of $693.18 million, a PE ratio of 29.37 and a beta of 0.24. Mesa Laboratories, Inc. has a 52-week low of $122.35 and a 52-week high of $224.95. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.10 and a quick ratio of 1.55.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Tuesday, July 31st. The medical instruments supplier reported $1.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.27. The company had revenue of $25.14 million during the quarter. Mesa Laboratories had a negative net margin of 0.25% and a positive return on equity of 15.92%. As a group, analysts anticipate that Mesa Laboratories, Inc. will post 7.09 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 17th. Stockholders of record on Friday, November 30th will be given a $0.16 dividend. The ex-dividend date of this dividend is Thursday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.35%. Mesa Laboratories’s payout ratio is presently 10.36%.

A number of brokerages have recently issued reports on MLAB. BidaskClub raised shares of Mesa Laboratories from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 26th. TheStreet cut shares of Mesa Laboratories from a “b-” rating to a “c” rating in a research report on Tuesday, August 21st. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $248.00 target price for the company in a research report on Wednesday, July 11th. Finally, ValuEngine cut shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th.

Several institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of Mesa Laboratories by 7.2% in the second quarter. Northern Trust Corp now owns 48,167 shares of the medical instruments supplier’s stock valued at $10,167,000 after acquiring an additional 3,222 shares during the period. Bank of New York Mellon Corp raised its stake in Mesa Laboratories by 5.4% in the second quarter. Bank of New York Mellon Corp now owns 18,858 shares of the medical instruments supplier’s stock valued at $3,980,000 after purchasing an additional 958 shares in the last quarter. Millennium Management LLC acquired a new position in Mesa Laboratories in the second quarter valued at about $3,888,000. Paloma Partners Management Co acquired a new position in Mesa Laboratories in the second quarter valued at about $284,000. Finally, Bank of America Corp DE raised its stake in Mesa Laboratories by 126.2% in the second quarter. Bank of America Corp DE now owns 3,939 shares of the medical instruments supplier’s stock valued at $832,000 after purchasing an additional 2,198 shares in the last quarter. 71.91% of the stock is owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

See Also: Technical Analysis

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply